Src Activation Aggravates Podocyte Injury in Diabetic Nephropathy via Suppression of FUNDC1-Mediated Mitophagy

Ting Zheng1, Han-Yu Wang1, Yang Chen1

  • 1Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Insights

c-Src (Src) activation drives diabetic nephropathy by inhibiting FUNDC1-mediated mitophagy, leading to mitochondrial damage and kidney dysfunction. Inhibiting Src protects against these effects, highlighting a new therapeutic target for DN.

Area of Science:

  • Cell Biology
  • Nephrology
  • Biochemistry

Background:

  • Diabetic nephropathy (DN) involves impaired mitochondrial function and mitophagy.
  • Regulatory mechanisms of mitophagy in DN progression are not fully understood.

Purpose of the Study:

  • To investigate the role of c-Src (Src) and FUNDC1-mediated mitophagy in DN development.
  • To explore Src as a potential therapeutic target for DN.

Main Methods:

  • Established a DN mouse model using db/db mice and treated with a Src inhibitor (PP2).
  • Assessed kidney function, renal histopathology, apoptosis, and mitophagy markers (LC3, p62).
  • Conducted in vitro studies using high glucose-treated human podocytes with PP2 or FUNDC1 siRNA.

Main Results:

  • Src activation was elevated in DN kidneys, correlating with mitochondrial damage, podocyte apoptosis, and dysfunction.
  • PP2 treatment ameliorated mitochondrial damage and podocyte apoptosis in vivo and in vitro.
  • High glucose increased Src activation, inhibiting mitophagy via FUNDC1 phosphorylation; FUNDC1 silencing reversed PP2's protective effects.

Conclusions:

  • Src activation suppresses FUNDC1-mediated mitophagy, contributing to diabetic renal damage.
  • Targeting Src may offer a therapeutic strategy for mitigating DN progression.